Sohini Das
 "Sohini Das")
Sohini Das
Sohini Das leads the automobile and healthcare verticals at Business Standard. In her 17 years as a journalist, she has written on myriad subjects and sectors -- FMCG, dairies, tourism, and state elections, among others, across Kolkata, Ahmedabad and now Mumbai. She loves doing personality stories and ground reportage.
Sohini Das leads the automobile and healthcare verticals at Business Standard. In her 17 years as a journalist, she has written on myriad subjects and sectors -- FMCG, dairies, tourism, and state elections, among others, across Kolkata, Ahmedabad and now Mumbai. She loves doing personality stories and ground reportage.
Page 87 - Sohini Das
Vaccine firms Bharat Biotech, Serum Institute patch up after war of words
Adar Poonawalla and Krishna Ella issue joint statement saying they would work together to roll out Covid-19 vaccine
 "Vaccine firms Bharat Biotech, Serum Institute patch up after war of words")
Bharat Biotech chief takes on Serum Institute in Covid-19 vaccine war
Krishna Ella turns the tables on critics, questions approval granted to Oxford-Astra vaccine
 "Bharat Biotech chief takes on Serum Institute in Covid-19 vaccine war")
Covishield to cost Rs 200/dose for first 100 mn doses to govt: Serum CEO
MRP for private market Rs 1,000/ dose; current licence does not allow export or sale in private market
 "Covishield to cost Rs 200/dose for first 100 mn doses to govt: Serum CEO")
Serum, Bharat Biotech vaccines get restricted use approval from DCGI
While the Oxford-AstraZeneca vaccine made by Serum Institute here has 70.42% efficacy, Bharat Biotech's still does not have efficacy data as trials are underway in India
 "Serum, Bharat Biotech vaccines get restricted use approval from DCGI")
A jab at risk: Serum's quest to lead the world in Covid-19 vaccine race
It took a chance by ramping up capacity on vaccines when they were yet to be approved and is set to emerge a global winner
 "A jab at risk: Serum's quest to lead the world in Covid-19 vaccine race")
Controversy around Bharat Biotech's Covaxin approval without efficacy data
Bharat Biotech's Covaxin is based on a whole inactivated virus platform, an old technology which is used to make vaccines given to infants
 "Controversy around Bharat Biotech's Covaxin approval without efficacy data")
Pharma exports likely to get a boost on coronavirus vaccine shots
However, he said that many countries, especially the European Union, are likely to step up production and increase their portfolios in an attempt to reduce import reliability.
 "Pharma exports likely to get a boost on coronavirus vaccine shots")
Covishield moves closer to roll-out; SII gets in-principle nod from panel
India would need 30 million doses in the first phase when it vaccinates the essential services workers including health care professionals, municipal and police staff, etc
 "Covishield moves closer to roll-out; SII gets in-principle nod from panel")
Serum Institute gets SEC thumbs up; Bharat Biotech proposal being discussed
US giant Pfizer did not come to present its case on Friday before the Subject Expert Committee
 "Serum Institute gets SEC thumbs up; Bharat Biotech proposal being discussed")
Serum Institute to seek nod for two full-dose regimen of Covishield
Suresh Jadhav, executive director of the Pune-based firm, said on Friday Serum was seeking approval from the Drug Controller General of India (DCGI) for the two-full dose regimen
 "Serum Institute to seek nod for two full-dose regimen of Covishield")
State governments may use bank guarantees to buy Covid-19 vaccines
Advice comes from Centre; some states begin talks with pharma firms
 "State governments may use bank guarantees to buy Covid-19 vaccines")
Vial, syringe makers push the pedal as Covid-19 vaccine roll-out nears
Most firms plan to increase capacity to meet fresh orders
 "Vial, syringe makers push the pedal as Covid-19 vaccine roll-out nears")
Covaxin's phase 1 trial data shows robust response: Bharat Biotech
Bharat Biotech had recently sought an accelerated approval from the regulator based on phase 1 and phase 2 studies
Govt in talks with Moderna for vaccine, yet to receive cold chain plan
Moderna's vaccine can be stored at normal fridge temperatures of 2 to 8 degrees Celsius for 30 days and it can be stored up to six months at minus 20 degree Celsius, according to reports
 "Govt in talks with Moderna for vaccine, yet to receive cold chain plan")
Pfizer may price Covid-19 vaccine lower in India than in UK and US
Cold chain of agriculture research body may come in handy
 "Pfizer may price Covid-19 vaccine lower in India than in UK and US")
Serum likely to submit final Covid-19 vaccine trial data in 10 days
If the data is found satisfactory, an approval for Covishield, Oxford-AstraZeneca's vaccine candidate, can come in by the first week of January
 "Serum likely to submit final Covid-19 vaccine trial data in 10 days")
Centre may not procure Pfizer-BioNTech Covid vaccine over high cost
At $37 per dose, the Pfizer vaccine is much more expensive compared to $3 per dose for the Covishield
 "Centre may not procure Pfizer-BioNTech Covid vaccine over high cost")
Shelf life of vaccines likely to be more than 3 months, unlike drugs
They have the stability data for these investigational products, said a source
 "Shelf life of vaccines likely to be more than 3 months, unlike drugs")
Recruited 8,000 volunteers already for phase 3 trials: Bharat Biotech head
The company says they are '200% transparent' about serious adverse events with regulator
 "Recruited 8,000 volunteers already for phase 3 trials: Bharat Biotech head")
ZyCoV-D shot can remain stable at room temperature: Zydus Cadila chairman
The company plans to apply for approval once it finishes phase 3 trials
 "ZyCoV-D shot can remain stable at room temperature: Zydus Cadila chairman")
